OPDP Year in Review: Highlights and Key Takeaways from 2022 FDA Enforcement Letters

On January 26th, join Jennifer A. Romanski, principal at Porzio, Bromberg & Newman, and Managing Director at Porzio Life Sciences, an RLDatix Company, as she highlights key aspects of warning and untitled letters issued by FDA’s Office of Prescription Drug Promotion (“OPDP”) in 2022, considers trends based on FDA’s guidance and prior enforcement letters, and reminds viewers of related regulatory requirements.